This Week in The Roadhouse Pharmacy

THE ROADHOUSE PHARMACY: There’s a great deal of interest in the Bio-tech sector at the moment, so we have opened our own Pharmacy to keep our readers up to speed.

SomnoMed open for business in Finland

SomnoMed (ASX: SOM) has announced the commencement of operations in Finland. READ MORE…

Admeus enjoys CardioCel six year celebration

Admedus (ASX: AHZ) announced that six years post implantation CardioCel® continues to show no level of calcification or any other issues. READ MORE…

pSivida subsidiary strikes distribution agreement

pSivida Corp. (ASX: PVA), a company that specialises in the development of sustained release, drug delivery products for treating eye diseases, announced that its licensee Alimera Sciences has signed an exclusive agreement with Specialised Therapeutics Australia (STA). READ MORE…

OBJ Limited signs suite of agreements with Proctor and Gamble

OBJ Limited (ASX: OBJ) has entered into a suite of agreements with Procter and Gamble (P&G), the world’s largest consumer products company. READ MORE…

Progen Pharmaceuticals granted US Patent notice

Progen Pharmaceuticals (ASX: PGL) has been granted a notice of allowance by the United States Patent and Trademark Office (USPTO) for Patent Application No. 12/738552 ‘Novel Sulfated Oligosaccharide Derivatives’, which includes Phase I cancer drug PG545. READ MORE…

Sheffield Resources fires up Thunderbird

THE INSIDE STORY: Minerals sands developer Sheffield Resources (ASX: SFX) recently reached a major milestone for a junior mining play, as the company’s market cap hurdled over the $100 million mark.

The rise in Sheffield’s share price flowed on the back of results from a Scoping Study conducted on the company’s 100 per cent-owned Thunderbird deposit, located near Derby in northwest Western Australia.

 

“It seems we released the results at just the right time and we are hoping that run continues to enable us to catch the forecast upswing in mineral sands commodity prices,” Sheffield Resources managing director Bruce McQuitty told The Resources Roadhouse.

“There was a boom in mineral sands prices in 2011, which has come off to what appears to be a floor level, with many analysts now forecasting improved demand and subsequently improved prices.”

The Scoping Study has determined Thunderbird to be a world-class, long life mineral sands project, which is anticipated to provide exceptional financial returns with modest capital requirements.

The Study results and subsequent share price movement are important milestones for Sheffield as it demonstrates the market’s recognition and appreciation of the significance of the Thunderbird project to the Australian minerals sands industry.

“We consider Thunderbird to be a company making project,” McQuitty said.

“It has shown itself to be so since the early days, and everything we have achieved there so far has done little to change our thinking.”

What Sheffield has achieved so far at Thunderbird has shown just because such a project is being developed by a junior mining company doesn’t mean it can’t be of significance on a global scale.

The company acquired Thunderbird as part of the Dampier project in late 2010 after Rio Tinto (ASX: RIO) had let ownership of the title slip due to difficulties associated with the GFC.

“At the time our technical director David Archer recognised the project’s potential and put an exploration target on it based on the Rio drilling, which consisted of just eight holes,” McQuitty said.

“He estimated an exploration target of between 450 to 850 million tonnes at five to ten per cent Heavy Minerals.”

Sheffield raised $10 million on the back of that target, which it has since put to good work.

The release of the Scoping Study followed a Resource upgrade completed earlier this year, when Sheffield doubled the Resource at Thunderbird, placing a lot more in the Indicated category.

The Resource at Thunderbird now sits at 2.62 billion tonnes at 6.5 per cent heavy minerals (HM) (Measured, Indicated and Inferred) for 170Mt of contained HM, including a high-grade component of 740Mt at 12.1 per cent HM.

The Scoping Study concluded projected and estimated production and financial parameters for the Thunderbird deposit to include:

An initial mine life of 32 years, targeting first production in 2017;

Life of mine (LOM) revenue of $10 billion;

LOM operating cash flow of $5 billion ($204 million per annum for first 10 years of production);

Average LOM annual EBITDA of $140 million ($187 million per annum for first 10 years of production);

Pre-production capital expenditure of $257 million plus $37 million of contingency, with identified opportunities that may reduce capital expenditure with capital payback in two years; and

Average annual production of 118,200 tonnes zircon, 545,000 tonnes ilmenite, and 21,700 tonnes of HiTi80 leucoxene.

Notably the Study has only incorporated Thunderbird’s Indicated and Measured Mineral Resources.

The high-grade Inferred segment of the Resources remains open in several directions and provides Thunderbird with a healthy amount of upside potential.

Sheffield has commenced pre-feasibility studies with completion anticipated Q1 2015, which according to a research note from Hartleys has potential to improve on the strong economics outlined by the Scoping Study.

The potential improvements identified by Hartleys include: A reduction in the start-up capital expenditure; reducing operating expenses; and increasing the current 32 year mine life.

“There is a lot of work associated with the pre-feasibility and feasibility stages such as groundwater, geotechnical, and infrastructure studies along with further metallurgical work to enhance our recovery rates and the associated process design,” McQuitty explained.

“We also anticipate undertaking a lot more drilling during the upcoming field season as we work towards moving more of the current Resource into the Measured category in the up-dip region where we plan to commence mining.

“There is more exploration to be done, simply because we have yet to fully close off the deposit, so there is a lot more drilling to do and a lot more news to come.

“The Scoping Study was quite thorough and some aspects are already at a pre-feasibility level, such as the process design and the metallurgical work.

“Other aspects of the Scoping Study, of course, were more educated assumptions, based on analogies with other projects – so we need to balance those up for the pre-feasibility study to ensure we have – not definitive data – but, more refined data.”

The Scoping Study has demonstrated Thunderbird is a global-scale deposit with potential to generate consistently strong cash margins from globally significant levels of production of ilmentie and zircon over a 32 year mine life.

The real excitement, however, is generated from the project’s current modelled production rates, from which Thunderbird is expected to supply approximately eight per cent and four per cent of the global zircon and ilmenite markets respectively.

Zircon is a high-value commodity. With the current zircon price around US$1200 per tonne.

Ilmenite is a staple feedstock of smelters, which enjoys a particularly higher demand from Chinese sulphate plants.

One major positive aspect of ilmenite is that even when markets tighten, demand for it doesn’t dissipate, whereas the market for the higher value, high-titanium feedstocks such as rutile, or synthetic rutile, does dry up.

Most of the major deposits around the world, in Africa and Sri Lanka, tend to be high in titanium minerals but not so high in zircon while others may be high in zircon, but not in titanium minerals.

The contained zircon in the total Resource at Thunderbird is more than any other deposit around the world at the present time.

The key to the project is its ‘high-grade zone’.

Modelling of the Thunderbird deposit resembles a layered sponge cake with the high-grade zircon and ilmenite zone being the jam and cream sitting in the middle as a coherent high-grade layer just below surface.

 

“This high-grade zone we are focussing on at Thunderbird has one of the highest grades, both in terms of zircon and titanium minerals of any deposit globally,” McQuitty said.

“We have a good balance at Thunderbird in terms of the mineral commodities represented.

“The bulk of the value within the Thunderbird deposit is tied up in the levels of zircon present, which account for some fifty per cent of the revenues defined in the Scoping Study, with around forty per cent coming from the ilmenite.

“Mineral sands is a bit of a blank box for many people and as such are something of an unknown quantity for many market watchers.

“We are very happy to finalise the Scoping Study and get the results out as we feel they fully explain the value of the high grades encompassed in the deposit in both dollar and production terms.”

Sheffield Resources Limited (ASX: SFX)
…The Short Story

HEAD OFFICE
Level 1, 57 Havelock Street
West Perth WA 6005

Ph: + 61 8 6424 8440
Fax:   +61 8 9321 1710

Email: info@sheffieldresources.com.au
Website: www.sheffieldresources.com.au

DIRECTORS and MANAGEMENT
Will Burbury, Bruce McQuitty, David Archer

MAJOR SHAREHOLDERS
Will Burbury            6.4%
Bruce McQuitty        6.4%
David Archer        6.4%

SHARES ON ISSUE
approx. 119.6 million

MARKET CAPITALISATION

$117.79 million (at 24/4/14)

 

 

Cobre Montana drills encouraging results in Chile

THE DRILL SERGEANT: Cobre Montana (ASX: CXB) has received encouraging results from a 12 hole diamond core drilling project completed at the company’s Mantos Grandes project in central Chile.

 

Mantos Grandes summary drill hole intersection plan. Source: Company announcement

 

Eight of the holes were drilled to investigate copper and gold mineralisation the company had identified adjacent to historic underground workings at Mantos Grandes.

Cobre Montana said the drilling at the historic workings at Mantos Grandes had confirmed broad zones of gold and copper mineralisation with results including”

9.2 metres at 0.83 grams per tonne gold and 0.29 per cent copper.

Another three holes were designed to test extensions at La Demonia to high-grade copper (chalcocite) and gold mineralisation that had been observed in adits.

High-grade gold intercepts encountered at La Demonia returned:

2m at 6.88g/t gold.

At Agua del Minero, a sub-vertical, east-west trending fault was investigated with a single drill hole, which intersected mineralisation at a down hole depth of 58m.

Anomalous assays were recorded over a one metre zone of 0.04g/t gold, 0.2 per cent copper, and 3g/t silver.

“The results indicate significant mineralisation remains above the areas of historic mining at Mantos Grandes and that there is good potential for further high-grade gold mineralisation at La Demonia,” Cobre Montana managing director Adrian Griffin said in the company’s announcement to the Australian Securities Exchange.

“Drilling has clearly demonstrated the continuity of the Agua del Minero feeder structure providing future targets in that area.

“These results, together with previously announced surface sampling on strike extensions of the orebodies, demonstrate a high probability of future success.”

Email: info@cobremontana.com.au

Website: www.cobremontana.com.au

Latin Resources defines copper-gold system at Ilo Este

THE DRILL SERGEANT: Latin Resources (ASX: LRS) has received results from a series of exploration activities recently undertaken at the company’s 100 per cent-owned Ilo Este project in Peru.

 

Location of Ilo Este project and 10 other target areas within
Latin’s over 100,000 hectare concession holding in the Southern Peru
copper district. Source: Company announcement

 

The actives included surface (soil and rock chip) geochemistry, a ground magnetic survey and specialised geological and alteration mapping, the combined efforts of which the company considers to have defined a major copper-gold porphyry system and a number of associated drill targets.

Eighty-one rock chip samples returned assay results ranging from 0.002 per cent to 0.37 per cent copper (average 0.15 per cent copper, exclusive of three high-grade results of 0.82 per cent, 1.1 per cent and 8.4 per cent copper).

Sixty-seven soil samples returned assay results ranging from 0.001 per cent to 0.31 per cent copper (average 0.039 per cent copper).

Latin explained anomalous samples have been found over approximately three square kilometres, which has roughly defined the extent of the Porphyry system as mapped.

Both the mapped extent and anomalous soils are open with coincident anomalies of gold and molybdenum are associated with the copper.

Geological and alteration mapping has confirmed an exposed copper-gold porphyry system, which appears to extend to the east, and may also be displaced into the hanging wall of a major low angle fault.

The company completed a ground magnetic survey over the exposed part of the porphyry system and part of the covered area to the east, from which the most notable result from this survey was the identification of a magnetic anomaly, 800m by 300m, within the Northern belt, and modelled to commence from 100 m below surface.

“We are extremely pleased…with these excellent results at Ilo Este and we are confident this project will add significant value to the Company going forward,” Latin Resources managing director Chris Gale said in the company’s announcement to the Australian Securities Exchange.

“By applying systematic exploration methodology, we have not only defined a significant exposed copper-gold porphyry system that extends well beyond historical drill testing, but we have also identified significant upside potential under cover to the east.”

“Now that Ilo Norte is being drilled by our JV partners, Latin’s priority at Ilo Este is to focus on unlocking more value at by drilling the project as soon as possible.”

Email: info@latinresources.com.au

Website: www.latinresources.com.au

pSivida subsidiary strikes distribution agreement

THE ROADHOUSE PHARMACY: pSivida Corp. (ASX: PVA), a company that specialises in the development of sustained release, drug delivery products for treating eye diseases, announced that its licensee Alimera Sciences has signed an exclusive agreement with Specialised Therapeutics Australia (STA).

The agreement is for the distribution in Australia and New Zealand of ILUVIEN® for the treatment of diabetic macular edema (DME).

pSivida explained that under the agreement, STA will be responsible for all regulatory and commercial activities for ILUVIEN in those countries.

The agreement between Alimera and STA will include a milestone payment to Alimera for achievement of a public reimbursement listing, and royalties based on net sales that will increase if a sales target is met.

pSivida is entitled to 20 per cent of royalties and 33 per cent of all other payments received by Alimera, including milestones.

“We are pleased to see this agreement for the commercialisation of ILUVIEN for DME in Australia and New Zealand and the potential for patients in those countries suffering from chronic DME to be treated with ILUVIEN,” pSivida president and CEO Dr. Paul Ashton said in the company’s announcement to the Australian Securities Exchange.

pSivida described STA to be a biopharmaceutical company dedicated to working with leading biotechnology and pharmaceutical companies worldwide to make specialised therapies available to people living in Australia and New Zealand.

The STA therapeutic portfolio and pipeline currently encompasses oncology, hematology, ophthalmology and infectious diseases.

STA also has interests in the therapeutic areas of respiratory, dermatology, endocrinology and central nervous system.

Website: www.psivida.com

Cleveland Mining encounters Brazilian iron ore

THE DRILL SERGEANT: Cleveland Mining Company (ASX: CDG) has completed its first pass drilling campaign on the Bahmex iron ore exploration projects in Bahia State, Brazil, as stage 1 of an earn-in process being undertaken by the Cleveland/ BC Iron (ASX: BCI) Alliance.

 

Source: Company announcement

 

Cleveland said the drilling program has intersected iron ore within the main target zone at the Caetite 2 projects, and encouraging intersections on all other prospects.

“This is an exciting result for the Alliance,” Cleveland Mining managing director David Mendelawitz said in the company’s announcement to the Australian Securities Exchange.

“We have started on the projects in Bahia, as opposed to the much larger projects in Minas Gerais, due to the Bahia projects’ close proximity to an open access railway currently being constructed and the extensive outcrop.

“The drilling clearly demonstrates that there is enough iron ore to justify further work on the projects.”

Cleveland said five prospects of the 26 tenements held in the package in which the Alliance has the option to acquire, have been drill tested to determine prospectivity and areas of focus for follow-up drilling programs.

All five prospects drilled, apart from Silvestre, have demonstrated to justify further work, which has now begun.

This will include metallurgical test-work, mine-gate point of sale studies and design of further drilling programs to delineate JORC resources.

Email: investors@clevelandmining.com.au

Website: www.clevelandmining.com.au

Argonaut signs on Antofagasta at Lumwana West

THE BOURSE WHISPERER: Argonaut Resources (ASX: ARE) has executed an option agreement with a wholly-owned subsidiary of global copper giant Antofagasta PLC for the exploration and development of the company’s Lumwana West project in Zambia.

 

The Domes Region in North Western Zambia showing the Lumwana West
licence, 2014 drill targets and surrounding mines. Source: Company
announcement

 

The deal means the Lumwana West project is fully funded to production with Antofagasta able to earn 70 per cent by spending US$18.9 million on exploration plus the amount required to complete a feasibility study to international standards.

If the project is feasible, Argonaut can be either carried into production or bought-out prior to construction.

Antofagasta is to become a cornerstone shareholder in Argonaut via a US$1.1 million placement, with funds to be used to increase Argonaut’s interest in the Lumwana West project to 90 per cent.

Argonaut explained the agreement covers all phases of the project’s development from regional exploration to the completion of a feasibility study and, in the event the project is moved forward and Argonaut decides not to fund its pro-rata share of the project, it will be either carried into production or be bought-out at the value of its interest.

“The implications of this agreement are considerable,” Argonaut Resources director Lindsay Owler said in the company’s announcement to the Australian S3ecurities Exchange.

“The Lumwana West project is now fully funded with a timetable for development.

“Project funding provided via the agreement together with recently announced capital raising programs sees Argonaut’s capital requirements met.”

Owler said the company anticipates major exploration work will commence at Lumwana West in May 2014.

“This work will include diamond-core drilling targeting extensions and repetitions of the Nyungu deposit plus discovery phase drilling at the West Mwombezhi and Kavipopo prospects,” he said.

“The tenor of these targets, the scarcity of emerging copper mines and the global decrease in exploration activity makes this work internationally significant.”

Email: adelaide@argonautresources.com

Website: www.argonautresources.com

Progen Pharmaceuticals granted US Patent notice

THE ROADHOUSE PHARMACY: Progen Pharmaceuticals (ASX: PGL) has been granted a notice of allowance by the United States Patent and Trademark Office (USPTO) for Patent Application No. 12/738552 ‘Novel Sulfated Oligosaccharide Derivatives’, which includes Phase I cancer drug PG545.

The company said the patent protects the composition and use of, and methods of treatment for Progen’s clinical compound PG545 and related PG500 series compounds.

The methods of treatment encompass a variety of therapeutic areas and include oncology, namely to control angiogenesis and metastasis.

The patent will provide protection and exclusivity until 2028 and may be further extended under certain circumstances.

“The allowance of this key USA patent is a significant milestone and valuable addition to the company’s intellectual property portfolio,” Progen Pharmaceuticals acting managing director Heng Tang said in the company’s announcement to the Australian Securities Exchange.

PG545 is currently being tested in a Phase I clinical trial in advanced cancer patients in Australia.

Website: www.progen-pharma.com

OBJ Limited signs suite of agreements with Proctor and Gamble

THE ROADHOUSE PHARMACY: OBJ Limited (ASX: OBJ) has entered into a suite of agreements with Procter and Gamble (P&G), the world’s largest consumer products company.

The agreements include a multi‐product development agreement (PDA) and an initial licensing agreement OBJ said sets the course to commercialise its magnetic micro‐array technology.

The PDA, Initial Licence and associated product development work plans comprise a multi‐product, multi‐category program that grants P&G world‐wide exclusive access to OBJ’s non‐powered micro‐array technology in specific consumer product categories.

The agreement package includes the over‐arching multi‐product and multi‐category PDA, the key terms of the master License that will apply to all new products developed under the PDA and work plans for the development of the first three products to utilize OBJ’s magnetic micro‐array technology, which includes the Initial Licence for the first of these products.

“The level of commitment over a number of years by the company’s key technical and management teams have been essential in achieving this important goal,” OBJ Limited non‐executive chairman Glyn Denison said in the company’s announcement to the Australian Securities Exchange.

Website: www.obj.com.au

LifeHealthcare strikes cardiology agreement with Biosensors

THE ROADHOUSE PHARMACY: LifeHealthcare Group Limited (ASX:LHC) has entered into an exclusive agreement with Biosensors Interventional Technologies Pte Ltd to distribute its range of interventional cardiology products in Australia for an initial term of two years.

LifeHealthcare said the deal marks the company’s entry into the interventional cardiology market, leveraging its existing strength in Cardiac Ultrasound.

Biosensors Interventional Technologies is a subsidiary of Biosensors International Group Ltd, the fourth largest interventional cardiology device company globally.

LifeHealthcare said Biosensors was among the first to recognise the potential clinical benefits offered by incorporating biodegradable polymer technology into drug-eluting stents (DES).

Biosensors product portfolio includes Drug-Eluding Stents, Bare Metal Stents, Balloon Dilatation Catheter and Drug Coated Stent products sold primarily to Interventional Cardiologists.

“Leveraging from our strength in Cardiac Ultrasound, we have been searching for the right partner and entry into the interventional cardiology market for some time.

“We are therefore thrilled to have Biosensors as our partner in this space,” LifeHealthcare chief executive officer Daren McKennay said in the company’s announcement to the Australian securities Exchange.

“We look forward to working with the Biosensors team to build market share in this important strategic product range for both companies, and extending our reach into the Australian medical device market.

“We are focussed on leveraging our existing and proven business model into new growth areas.

“This new agreement represents one of a number of potential step change growth projects and I am pleased to see this strategic milestone achieved.”

With all key products listed on the Australian Register of Therapeutic Goods and the Prosthesis List, the agreement is planned for immediate implementation in late FY14.

Website: www.lifehealthcare.com.au